Day: March 4, 2021

ALBIOMA : Résultats annuels 2020

Written by Customer Service on March 4, 2021. Posted in Earnings Releases And Operating Results.

Communiqué de presseParis La Défense, le 4 mars 2021Résultats annuels 2020Résultat net part du Groupe (RNPG) en forte hausse : + 25 % ; Croissance significative de l’EBITDA : +13 %Sécurisation de la croissance future : conversion 100 % biomasse et prolongation d’Albioma Bois-Rouge actées, 40 MWc remportés dans le photovoltaïque et entrée dans la géothermieEngagements structurants en faveur de la transition énergétique : mix énergétique de +90 % de renouvelable en 2025 et de près de 100 % en 2030Le Conseil d’Administration d’Albioma, réuni le 4 mars 2021 sous la présidence de Frédéric Moyne, a arrêté les comptes consolidés du Groupe pour l’exercice 2020.« Nous affichons pour l’exercice 2020 des résultats très solides, avec un EBITDA en croissance de 13 % et un RNPG en forte hausse de 25 %. Ces résultats sont le fruit du travail des équipes...

Dexia: Dexia Group consolidated results 2020

Written by Customer Service on March 4, 2021. Posted in Earnings Releases And Operating Results.

Please find enclosed Dexia Group consolidated results for 2020.AttachmentDexia FY 2020 results_EN_DEF

Dexia : Résultats consolidés 2020 du groupe Dexia

Written by Customer Service on March 4, 2021. Posted in Earnings Releases And Operating Results.

Veuillez trouver en pièce jointe les résultats consolidés du groupe Dexia pour l’exercice 2020.Pièce jointeDexia_FY 2020 results_FR_DEF

Dexia : Geconsolideerde resultaten 2020 van de groep Dexia

Written by Customer Service on March 4, 2021. Posted in Earnings Releases And Operating Results.

Gelieve in bijlage de geconsolideerde resultaten 2020 van de groep Dexia te willen vinden.BijlageDexia_FY 2020 results_NL_DEF

NexPoint Strategic Opportunities Fund Declares Initial Dividend for its 5.50% Series A Cumulative Preferred Shares

Written by Customer Service on March 4, 2021. Posted in Dividend Reports And Estimates.

DALLAS, March 04, 2021 (GLOBE NEWSWIRE) — NexPoint Strategic Opportunities Fund (NYSE: NHF) (“NHF” or the “Company”) today declared an initial pro-rated dividend for its 5.50% Series A Cumulative Preferred Shares (NYSE:NHF PR A) (“Preferred Shares”) of $0.3244382022 per share. The dividend will be payable on March 31, 2021, to Preferred shareholders of record at the close of business March 24, 2021. Dividends on the Preferred Shares will be payable quarterly on March 31, June 30, September 30 and December 31 at the rate of 5.5% per annum to holders of record at the close of business on the fifth preceding business day.The Company announced the pricing of the Preferred Shares offering on January 8, 2021. The Preferred Shares were issued on January 8, 2021 (the “Issuance Date”) and commenced trading on January 8, 2021. The initial...

Addex to Present at the H.C. Wainwright Global Life Sciences Conference

Written by Customer Service on March 4, 2021. Posted in Public Companies.

Geneva, Switzerland, March 4, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference (March 9-10, 2021).In his presentation, which is scheduled for Tuesday, March 9, 2021 at 07:00 ET, Mr Dyer will provide a corporate update and discuss recent developments at Addex. The video presentation will be available for viewing on-demand by registered participants via this link from the time of the presentation and subsequently on the Events page the Company’s website (www.addextherapeutics.com). The video replay will be archived for 90 days following the event.Management will be available for virtual one-on-one...

argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update

Written by Customer Service on March 4, 2021. Posted in Public Companies.

– Biologics License Application (BLA) for IV efgartigimod accepted for review by U.S. Food and Drug Administration (FDA) for generalized myasthenia gravis (gMG)– Pre-approval access program opened in U.S. and Europe for eligible gMG patients – Management to host conference call today at 2:30 pm CEST (8:30 am ET) –March 4, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today reported financial results for the full year 2020 and provided a fourth quarter business update.“2020 was an exceptional year for argenx, marked by execution across the organization and highlighted by the positive results of our pivotal Phase 3 ADAPT trial. We have started 2021 on strong...

FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma

Written by Customer Service on March 4, 2021. Posted in Public Companies.

FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthmaSubmission supported by data demonstrating Dupixent significantly reduced severe asthma attacks and is the only biologic to improve lung function in children aged 6 to 11 years with asthma in a randomized Phase 3 trial, while also further adding to the well-established safety profile of DupixentDupixent has the potential to be a best-in-class treatment option in this younger population of children aged 6 to 11Acceptance represents another milestone in the development of Dupixent in addressing diseases driven by type 2 inflammationPARIS and TARRYTOWN, N.Y. – March 4, 2021 – The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on treatment for...

La FDA accepte d’examiner Dupixent® (dupilumab) dans le traitement de l’asthme modéré à sévère de l’enfant

Written by Customer Service on March 4, 2021. Posted in Public Companies.

La FDA accepte d’examiner Dupixent® (dupilumab) dans le traitement de l’asthme modéré à sévère de l’enfantLa soumission prend appui sur des données ayant démontré que Dupixent réduit significativement les crises d’asthme et qu’il est le seul médicament biologique à améliorer la fonction respiratoire des enfants souffrant d’asthme, âgés de 6 à 11 ans, inclus dans un essai clinique randomisé de phase III, en plus de conforter son profil bien établi de tolérance. Dupixent a le potentiel de devenir la meilleure option thérapeutique de sa classe pharmacothérapeutique pour cette population d’enfants âgés de 6 à 11 ans.Une nouvelle étape du développement de Dupixent dans le traitement des maladies portant une signature inflammatoire de type 2 vient d’être franchie.PARIS et TARRYTOWN (New York) – Le 4 mars 2021 – La Food and Drug Administration...

Boskalis: operationally strong 2020, record order book and very solid financial position

Written by Customer Service on March 4, 2021. Posted in Public Companies.

Papendrecht, 4 March 2021‎HIGHLIGHTS 2020Revenue: EUR 2.5 billionEBITDA: EUR 404 millionOperating result: EUR 140 millionNet operating profit: EUR 90 millionExceptional charges: EUR 195 millionRecord order book: EUR 5.3 billionPositive net cash position of EUR 439 millionDividend proposal: EUR 0.50 per share all cashOUTLOOKVery well-filled order book provides solid foundation for 2021Dredging: gradual improvement in the course of 2021Offshore Energy: continuation of strong 2020 pictureImproved medium-term outlookRoyal Boskalis Westminster N.V. (Boskalis) has exceeded expectations in what has proven to be a very turbulent and challenging 2020 with an EBITDA of EUR 404 million. Net operating profit amounted to EUR 90 million. Furthermore, despite COVID-19 restrictions, many new projects were acquired resulting in a record high order book...

Day: March 4, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals